Search clinical trials for: GP MDI (PT001)

Total 5735 results

Pearl Therapeutics, Inc.

Completed

Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects

Healthy Volunteers

Australia
Pearl Therapeutics, Inc.

Completed

PT003 MDI Dose Confirmation Study

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD

COPD, Chronic Obstructive Pulmonary Disease

Belgium
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD

Chronic Obstructive Pulmonary Disease

United States, Germany, United Kingdom, China, Taiwan, Korea, Republic of, Japan, Czechia, Hungary, Poland, Russian Federation
Pearl Therapeutics, Inc.

Completed

Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®

COPD

Japan
Pearl Therapeutics, Inc.

Completed

Multi-Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD (PINNACLE 2)

Chronic Obstructive Pulmonary Disease (COPD)

United States
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
Pearl Therapeutics, Inc.

Withdrawn

To Assess the Efficacy and Safety of PT010 Compared to PT009 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease
Pearl Therapeutics, Inc.

Completed

PT003 MDI Cardiovascular Safety Study

Chronic Obstructive Pulmonary Disease

United States, Australia, New Zealand
Pearl Therapeutics, Inc.

Completed

Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD

COPD

United States
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, United States, New Zealand
Pearl Therapeutics, Inc.

Terminated

Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

COPD

United States
Pearl Therapeutics, Inc.

Completed

Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United States
Pearl Therapeutics, Inc.

Completed

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

Asthma

United States
Pearl Therapeutics, Inc.

Completed

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos) (KRONOS)

COPD

United States, Canada, China, Japan
Pearl Therapeutics, Inc.

Completed

Randomized, Crossover Safety and Pharmacokinetics Study of PT010

COPD

United States
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Effects of PT003 and Placebo MDI on Specific Image Based Airway Volumes and Resistance in Subjects With Moderate to Severe COPD

COPD

Belgium
Pearl Therapeutics, Inc.

Completed

Phase I Study Evaluating the Safety and Pharmacokinetics of Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (BGF MDI) in Healthy Volunteers

Healthy Volunteers

United States
Pearl Therapeutics, Inc.

Completed

PT001 MDI Versus Spiriva® in Patients With Moderate to Severe COPD

Chronic Obstructive Pulmonary Disease

United States
AstraZeneca
Parexel

Recruiting

Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma (ACADIA)

Asthma

United States
Pearl Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

Asthma

United States
Shanghai Vinnerna Biosciences Co., Ltd.

Withdrawn

Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets

Healthy Subjects

Australia
Pearl Therapeutics, Inc.

Completed

A Study to Assess the Efficacy and Safety of PT009 Compared to PT005 on COPD Exacerbations Over a 52-Week Period in Subjects With Moderate to Very Severe COPD (Sophos)

Chronic Obstructive Pulmonary Disorder

United States, Austria, Belgium, Canada, Denmark, Germany, Italy, Spain, Sweden, United Kingdom, Peru, Brazil, South Africa, Argentina, Russian Federation, Mexico, Puerto Rico, Chile, Norway
Krasnoyarsk Regional Hospital

Unknown

Safety Procedure Pulmonary Artery Denervation in Addition to Pulmonary Vein Isolation Combined With Ganglionated Plexi Ablation in Patients With Persistent Atrial Fibrillation and Pulmonary Hypertension

Pathologic Processes | Heart Diseases | Cardiovascular Diseases | Lung Diseases | Atrial Fibrillation | Arrhythmias, Cardiac | Hypertension, Pulmonary
Sun Yat-sen University

Not yet recruiting

Peramprizumab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Shanghai Vinnerna Biosciences Co., Ltd.

Recruiting

A Real-World Study of JT001 for COVID-19

COVID-19

China
Fudan University

Active, not recruiting

PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients

Triple Negative Breast Cancer

China
University of Malaga

Completed

Plus Deep Water Running on Low Back Pain (+DWR)

Low Back Pain

Spain
Shanghai JunTop Biosciences Co., LTD
Sponsor GmbH

Terminated

JT001 (VV116) for the Early Treatment of COVID-19

Mild to Moderate COVID-19

China, Hong Kong
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Recruiting

The Mass Balance Study of [14C]JT001

Healthy Subjects

China
Pinteon Therapeutics, Inc

Completed

Safety and Tolerability of PNT001 in Healthy Adults

Healthy

United States
Sun Yat-sen University

Recruiting

A Multi-center, Randomized, Double-blind, Phase II/III Clinical Trial of AK104 or Placebo in Combination With Chemotherapy as Second-line or More Lines for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

Recurrent or Metastatic Nasopharyngeal Carcinoma

China
Universitätsklinikum Hamburg-Eppendorf

Recruiting

Digital Tool Enhancing GPs' Information Management for Patients With Multimorbidity - a Pilot Study (gp-multitool)

Coronary Disease | Diabetes Mellitus, Type 2 | Breast Neoplasms | Diabetes Mellitus, Type 1 | Pulmonary Disease, Chronic Obstructive | Asthma | Comorbidities and Coexisting Conditions

Germany
University of Aarhus

Recruiting

Offering Cervical Cancer Screening to Older Women

Uterine Cervical Neoplasm | Mass Screening | Uterine Cervical Disease | Uterine Neoplasm

Denmark
University of Wisconsin, Madison
American Heart Association

Completed

Parent Communication for Feeding an Infant With a Heart Defect

Communication | Heart Defects, Congenital | Infant Conditions

United States
King's College London
South London and Maudsley NHS Foundation Trust

Completed

PRINCE Primary: Integrated GP Care for Persistent Physical Symptoms - a Feasibility & Cluster Randomised Controlled Trial (PRINCE Primary)

Persistent Physical Symptoms

United Kingdom
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

JT001 (VV116) for the Treatment of COVID-19

Mild to Moderate COVID-19

China
Novo Nordisk A/S

Completed

A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B (paradigm™7)

Congenital Bleeding Disorder | Haemophilia B

United States, Switzerland, Germany
Faculty Sao Leopoldo Mandic Campinas

Unknown

Endodontic Treatment Using CTZ Paste in Primary Teeth (SLM2204)

Pulpectomy Agents

Brazil
Cardiovascular Research Society, Greece

Completed

Circumferential Versus Ganglionated Plexi Ablation for Atrial Fibrillation (AF)

Atrial Fibrillation

Russian Federation, Greece
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Completed

A Study in Elderly Chinese Subjects With Underlying Diseases

Elderly Subjects With Underlying Diseases

China
Pearl Therapeutics, Inc.

Completed

Pharmacokinetics and Safety Study of PT010 and PT003 in Healthy Chinese Adult Subjects

Chronic Obstructive Pulmonary Disease

China
Sun Yat-sen University

Active, not recruiting

Phase Ⅲ Trial of Adjuvant Chemotherapy in Patients With N2-3 Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
University of Plymouth
Superfast Cornwall

Unknown

Do Superfast Broadband and Tailored Interventions Improve Use of E-health and Reduce Health Related Travel? (SUPFASTEHEALTH)

eHealth
SeeCure LLC

Unknown

The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer

Breast Cancer

United States
Shanghai Vinnerna Biosciences Co., Ltd.
Sponsor GmbH

Terminated

Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Moderate to Severe COVID-19

China, Uzbekistan
Pinteon Therapeutics, Inc
United States Department of Defense

Terminated

Safety and Tolerability of PNT001 in Patients With Acute Traumatic Brain Injury (TBI)

Traumatic Brain Injury

United States
Revance Therapeutics, Inc.

Completed

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

Facial Wrinkles | Lateral Canthal Lines | Crow's Feet

United States
University of La Laguna

Recruiting

Acceptance of Hepatitis C Screening by Self-testing in High Risk and General Population

Hepatitis C

Spain
Nantes University Hospital

Active, not recruiting

Cervical Cancer Screening Uptake: A Randomised Controlled Trial Assessing the Effect of Sending Invitation Letters to Nonadherent Women (IMPACTGP)

Cervical Cancer

France

3

Subscribe